Kindstar Globalgene Technology, Inc. released its 2026 interim results, showing modest top-line growth and a marked improvement in profitability.

Revenue and Profitability • Revenue climbed 3.7 % year on year to RMB 473.62 million. • Gross profit advanced 10.9 % to RMB 218.02 million; gross margin expanded to 46.0 % from 43.0 % a year earlier. • Loss attributable to shareholders narrowed 47.7 % to RMB 18.86 million, while loss before tax shrank 51.6 % to RMB 14.87 million, reflecting stronger operating leverage and tighter cost controls. • Net cash generated from operations reached RMB 40.08 million, reversing a RMB 33.77 million outflow in the prior-year period.

Segment Performance • Hematology remained the core pillar, contributing RMB 281.65 million (59 % of group revenue), up 1.8 %, with segment profit up 15.9 % to RMB 71.59 million. • Oncology revenue accelerated 73.8 % to RMB 32.10 million; segment loss narrowed to RMB 7.91 million from RMB 13.64 million. • Neurology delivered RMB 46.44 million, almost flat year on year, but lifted segment profit 6.4 % to RMB 10.13 million. • Scientific Research Services & CRO revenue eased 3.9 % to RMB 30.82 million; segment loss reduced to RMB 4.49 million. • Infectious Disease revenue fell 29.9 % to RMB 12.59 million amid post-pandemic normalisation.

Balance Sheet and Cash • Cash, cash equivalents and time deposits totalled RMB 1.74 billion at 30 June 2026. • Interest-bearing bank borrowings stood at RMB 368.75 million; gearing ratio was 14.0 %. • Net assets were RMB 2.64 billion.

Capital Allocation • Kindstar paid a FY 2025 final dividend of RMB 82.36 million; no interim dividend was declared. • During 1H 2026 the company repurchased 0.38 million shares for HK$0.38 million and bought 0.71 million shares (HK$0.60 million) for its RSU scheme. • Investment outlays included RMB 16.50 million for a 90 % stake in Shanghai Pillar Biotech, adding companion-diagnostics capability, and RMB 73.19 million in unlisted funds.

R&D and Innovation • R&D spending totalled RMB 44.90 million, focused on hematology, oncology and multi-omics platforms. • Forty-four patent applications were filed and thirty-six new R&D projects initiated during the period.

Management Outlook Kindstar Global intends to deepen its dual-growth strategy of “Hematology foundation, Oncology expansion,” leverage recently acquired assets (AnchorDx, Pillar Biotech, Kindstar Zhenyuan) to build a full-cycle precision-diagnostics portfolio, and allocate capital prudently towards regional laboratory penetration, technology platforms and synergistic M&A opportunities.